falsefalse

Post-Conference Perspectives: Understanding HER2-Low Breast Cancer - Episode 3

Treating HER2-low Breast Cancer With Novel Antibody Drug Conjugates

,

Experts take a look at clinical data behind novel antibody drug conjugates and consider how they may impact the management of HER2-low breast cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Current Landscape of HER2 Testing in Breast Cancer
    EP. 2: Strategies in Identifying and Stratifying HER2 Status in Breast Cancer
    Now Viewing
    EP. 3: Treating HER2-low Breast Cancer With Novel Antibody Drug Conjugates
    EP. 4: HER2-low Breast Cancer: Practical Applications of ADC Therapy

    Related Content:

    Post-Conference Perspectives: Understanding HER2-Low Breast CancerBreast Cancer
    CHMP Shares Positive Opinion for Denosumab Biosimilars for Osteoporosis and Skeletal-Related Cancer Complications
    Dr Hamilton on Vepdegestrant vs Fulvestrant in ER+/HER2-Negative Advanced Breast Cancer
    Higher Pretreatment HER2 Amplicon mRNA Signature Predicts Improved Outcomes With Trastuzumab Deruxtecan in Metastatic Breast Cancer
    x